Dong-A Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through a Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical trial to treat obesity; and STP0404 for the treatment of AIDS. It also provides medical devices and equipment; healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and cosmetics; health functional food; contract development and manufacturing organization for biosimilar and pharmaceutical products, and oligonucleotide therapeutics; functional sports drinks under the POCARI SWEAT brand; logistics and fulfillment services; glass bottles, PET bottles, aluminum and plastic caps, and paper packaging boxes; mineral and carbonated water, and mixed drinks; and IT and construction services. In addition, the company is involved in engineering; cargo, courier, and automobile transport arrangements; transportation warehousing and leasing; real estate development; agricultural product distribution; management consulting; business management; and architectural, electrical work, fire protection, and housing contracting services. The company was formerly known as Dong-A Socio Holdings Co., Ltd. and changed its name to Dong-A Pharmaceutical Co.,Ltd. in October 2026. Dong-A Pharmaceutical Co.,Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
Research context
Dong-A Socio Holdings Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Dong-A Socio Holdings Co., Ltd is currently in a long term uptrend where the price is trading 4.7% above its 200 day moving average.
From a valuation standpoint, the stock is 90.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.8.
Dong-A Socio Holdings Co., Ltd's total revenue rose by 5.8% to $195B since the same quarter in the previous year.
Its net income has increased by 4741.8% to $135B since the same quarter in the previous year.
Finally, its free cash flow grew by 805.5% to $10B since the same quarter in the previous year.
Based on the above factors, Dong-A Socio Holdings Co., Ltd gets an overall score of 5/5.